In the News

Dr. Richard P. Baum, was honored by the Society of Nuclear Medicine, India in Chennai on December 8, 2011 and received the AGASTHIAR AWARD for his "Life Time Contribution to The Field of Nuclear Medicine". Prof. Baum was also appointed "Visiting Professor" of the FM Medical University (Tandu Hospital) in Xi'an, Shaanxi, China where he initiated a project on Ga-68 imaging and PRRNT which will be the first place in China where THERANOSTICS will be performed. The initial effort for this

A method of molecular imaging that pinpoints hormonally active tissues in the body could change the course of treatment for a remarkable number of neuroendocrine cancer patients, say researchers at the Society of Nuclear Medicine's 59th Annual Meeting.

Results of the study indicated that PET/CT and Ga-68 DOTATATE was highly sensitive and specific for assessing neuroendocrine tumors and changed thecourse of treatment for a large number of patients. Prior to imaging, more than half of the

On April 10, 2012 a 42 center worldwide trial of PRRT using LU177 was announced with sites in the US and Europe.

Detailed Description:

A multicenter, stratified, open, randomized, comparator-controlled, parallel-group phase III study. In this study, treatment with 177Lu-DOTA0-Tyr3-Octreotate plus best supportive care (30 mg Octreotide LAR) will be compared to treatment with high dose (60 mg) Octreotide LAR in patients with inoperable, somatostatin receptor positive, histologically proven

Miami Beach, Fla. – The Society of Nuclear Medicine's (SNM) 2012 Image of the Year illustrates the effectiveness of Bi-213-DOTATOC for the peptide receptor alpha-therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that do not respond to beta therapy. Researchers selected this image from more than 2,000 studies presented over the course of four days during SNM's 2012 Annual Meeting in Miami Beach, Fla. To view the complete article, click here.